Your browser doesn't support javascript.
loading
Reengineering Ponatinib to Minimize Cardiovascular Toxicity.
Hnatiuk, Anna P; Bruyneel, Arne A N; Tailor, Dhanir; Pandrala, Mallesh; Dheeraj, Arpit; Li, Wenqi; Serrano, Ricardo; Feyen, Dries A M; Vu, Michelle M; Amatya, Prashila; Gupta, Saloni; Nakauchi, Yusuke; Morgado, Isabel; Wiebking, Volker; Liao, Ronglih; Porteus, Matthew H; Majeti, Ravindra; Malhotra, Sanjay V; Mercola, Mark.
Afiliação
  • Hnatiuk AP; Stanford Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, California.
  • Bruyneel AAN; Stanford Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, California.
  • Tailor D; Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health Sciences University School of Medicine, Portland, Oregon.
  • Pandrala M; Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health Sciences University School of Medicine, Portland, Oregon.
  • Dheeraj A; Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health Sciences University School of Medicine, Portland, Oregon.
  • Li W; Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health Sciences University School of Medicine, Portland, Oregon.
  • Serrano R; Stanford Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, California.
  • Feyen DAM; Stanford Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, California.
  • Vu MM; Stanford Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, California.
  • Amatya P; Stanford Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, California.
  • Gupta S; Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health Sciences University School of Medicine, Portland, Oregon.
  • Nakauchi Y; Division of Hematology Institute for Stem cell Biology and Regenerative Medicine, Stanford School of Medicine, California.
  • Morgado I; Stanford Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, California.
  • Wiebking V; Department of Pediatrics, Stanford School of Medicine, Stanford, California.
  • Liao R; Stanford Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, California.
  • Porteus MH; Department of Pediatrics, Stanford School of Medicine, Stanford, California.
  • Majeti R; Division of Hematology Institute for Stem cell Biology and Regenerative Medicine, Stanford School of Medicine, California.
  • Malhotra SV; Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health Sciences University School of Medicine, Portland, Oregon.
  • Mercola M; Stanford Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, California.
Cancer Res ; 82(15): 2777-2791, 2022 08 03.
Article em En | MEDLINE | ID: mdl-35763671
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piridazinas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Antineoplásicos Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Cancer Res Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piridazinas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Antineoplásicos Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Cancer Res Ano de publicação: 2022 Tipo de documento: Article